Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Jun
25
Today In Oncology
Early Palliative Care Improves Quality of Life for Patients With Breast Cancer in India
Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease
Advanced Breast Cancer Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
Educational Gaps Found in Cardio-Oncology Training
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo